Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | CA4 | P22748 | 1/20 | 0.41 |
| ▸ | CA6 | P23280 | 1/20 | 0.41 |
| ▸ | CA5A | P35218 | 1/20 | 0.41 |
| ▸ | CA7 | P43166 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.41 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 2/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 7/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | MMP8 | P22894 | 3/20 | 0.33 |
| ▸ | MMP12 | P39900 | 3/20 | 0.33 |
| ▸ | MMP13 | P45452 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12936109 | 0.85 | CA1 (0.39) | CA12CA1CA2CA4CA6 | |
| SCHEMBL4347849 | 0.84 | CA1 (0.43) | CA12CA1CA2CA4CA6 | |
| SCHEMBL15292050 | 0.83 | SKP2 (0.51) | HTR1AHTR1DHTR1BPTGS2PTGES2 | |
| SCHEMBL4186859 | 0.81 | CA12 (0.42) | CA12CA1CA2CA4CA6 | |
| SCHEMBL12017198 | 0.81 | CYP3A4 (0.53) | CA12CA1CA2CA4CA6 | |
| SCHEMBL1275321 | 0.76 | RECQL (0.58) | CA12CA1CA2CA6CA5A | |
| SCHEMBL1276240 | 0.76 | CA1 (0.51) | CA1CA2CA9HTR1AHTR1D | |
| Hydrochloric Acid SCHEMBL4731092 | 0.75 | RECQL (0.61) | CA12CA1CA2CA6CA5A | |
| SCHEMBL1275279 | 0.74 | MAPT (0.40) | CA12CA1CA2CA6CA5A | |
| SCHEMBL1852602 | 0.73 | CA2 (0.48) | CA12CA1CA2CA4CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8735589-B2 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735589-B2 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| US-8735589-B2 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2014-05-27 | — | — | US | disclosed |
| EP-2467373-B1 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LTD (IN) | 2013-10-02 | — | — | EP | disclosed |
| EP-2467373-B1 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LTD (IN) | 2013-10-02 | — | — | EP | disclosed |
| US-20120220778-A1 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| US-20120220778-A1 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| US-20120220778-A1 | Process for the synthesis of naratriptan | CIPLA LIMITED (IN) | 2012-08-30 | — | — | US | disclosed |
| EP-2467373-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | Cipla Limited (IN) | 2012-06-27 | — | — | EP | disclosed |
| WO-2011021000-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
| WO-2011021000-A2 | A PROCESS FOR THE SYNTHESIS OF NARATRIPTAN | CIPLA LIMITED (IN) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220778-A1 | Process for the synthesis of naratriptan | ZFR, SPR, NPSR1 | CA12 1233/4885CA1 1104/4885CA2 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.